These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20889597)

  • 1. Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter?
    Jawaheer D; Maranian P; Park G; Lahiff M; Amjadi SS; Paulus HE
    J Rheumatol; 2010 Dec; 37(12):2475-85. PubMed ID: 20889597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis -- results from the DANBIO registry.
    Jawaheer D; Olsen J; Hetland ML
    J Rheumatol; 2012 Jan; 39(1):46-53. PubMed ID: 22089458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis.
    Weng HH; Ranganath VK; Khanna D; Oh M; Furst DE; Park GS; Elashoff DA; Sharp JT; Gold RH; Peter JB; Paulus HE;
    J Rheumatol; 2010 Mar; 37(3):550-7. PubMed ID: 20110517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs.
    Paulus HE; Di Primeo D; Sharp JT; Genant HK; Weissman BN; Weisman MH; Sanda M;
    J Rheumatol; 2004 Mar; 31(3):470-81. PubMed ID: 14994390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study.
    Sokka T; Toloza S; Cutolo M; Kautiainen H; Makinen H; Gogus F; Skakic V; Badsha H; Peets T; Baranauskaite A; Géher P; Ujfalussy I; Skopouli FN; Mavrommati M; Alten R; Pohl C; Sibilia J; Stancati A; Salaffi F; Romanowski W; Zarowny-Wierzbinska D; Henrohn D; Bresnihan B; Minnock P; Knudsen LS; Jacobs JW; Calvo-Alen J; Lazovskis J; Pinheiro Gda R; Karateev D; Andersone D; Rexhepi S; Yazici Y; Pincus T;
    Arthritis Res Ther; 2009; 11(1):R7. PubMed ID: 19144159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Radiographic Outcomes in Patients Diagnosed with Early Rheumatoid Arthritis in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study.
    Haugeberg G; Bøyesen P; Helgetveit K; Prøven A
    J Rheumatol; 2015 Dec; 42(12):2279-87. PubMed ID: 26568592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort.
    Khanna D; Oh M; Furst DE; Ranganath V; Gold RH; Sharp JT; Park GS; Keystone EC; Paulus HE;
    Arthritis Rheum; 2007 Apr; 57(3):440-7. PubMed ID: 17394230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study.
    Courvoisier N; Dougados M; Cantagrel A; Goupille P; Meyer O; Sibilia J; Daures JP; Combe B
    Arthritis Res Ther; 2008; 10(5):R106. PubMed ID: 18771585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis.
    Combe B; Cantagrel A; Goupille P; Bozonnat MC; Sibilia J; Eliaou JF; Meyer O; Sany J; Dubois A; Daurès JP; Dougados M
    J Rheumatol; 2003 Nov; 30(11):2344-9. PubMed ID: 14677175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis).
    Lukas C; Combe B; Ravaud P; Sibilia J; Landew R; van der Heijde D
    Arthritis Rheum; 2011 Jul; 63(7):1804-11. PubMed ID: 21452295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
    Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
    Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs.
    Mjaavatten MD; Radner H; Yoshida K; Shadick NA; Frits ML; Iannaccone CK; Kvien TK; Weinblatt ME; Solomon DH
    Semin Arthritis Rheum; 2015 Feb; 44(4):399-404. PubMed ID: 25257807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database.
    Ranganath VK; Paulus HE; Onofrei A; Khanna D; Reed G; Elashoff DA; Kremer JM; Furst DE
    J Rheumatol; 2008 Oct; 35(10):1966-71. PubMed ID: 18785317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage.
    Ahlmén M; Svensson B; Albertsson K; Forslind K; Hafström I;
    Ann Rheum Dis; 2010 Jan; 69(1):230-3. PubMed ID: 19158113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96.
    Gordon P; West J; Jones H; Gibson T
    J Rheumatol; 2001 Nov; 28(11):2409-15. PubMed ID: 11708411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with Early Rheumatoid Arthritis in the 2000s Have Equal Disability and Pain Despite Less Disease Activity Compared with the 1990s: Data from the BARFOT Study over 8 Years.
    Andersson MLE; Forslind K; Hafström I;
    J Rheumatol; 2017 Jun; 44(6):723-731. PubMed ID: 28365578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.